Heptares Therapeutics and Kymab Ltd. have entered into a strategic collaboration to discover, develop and commercialize antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. GPCRs act at critical checkpoints that can be targeted by immunotherapy antibodies.   Heptares will apply its StaR platform to create stable antigens based on multiple GPCR targets chosen by the companies. Kymab will then use its Kymouse human antibody disc...